Celltrion Unveils Ambitious Drug Pipeline at J.P. Morgan Conference

Celltrion, a leading global biopharmaceutical company, has outlined its strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference. The company, known for its pioneering work in antibody biosimilars, is now expanding its expertise into advanced modalities such as antibody-drug conjugates (ADCs) and multi-specific antibodies. This move aligns with Celltrion's dual-track approach, focusing on both biosimilars and innovative drug development to drive sustainable growth.



At the conference, Celltrion revealed specific timelines and milestones for its 13 innovative drugs through 2028, including 9 ADCs and 4 multi-specific antibodies. The company plans to submit IND applications for these drugs sequentially, with the first four candidates expected to enter clinical trials in 2025. The IND submission timelines for each pipeline are as follows:

* 2025: 4 new drug candidates (2 ADCs and 2 multi-specific antibodies)
* 2026: 2 ADC candidates
* 2027: 3 ADC candidates
* 2028: 1 ADC candidate and 1 multi-specific antibody candidate



Celltrion's next-generation ADC platform includes two biobetter ADC candidates, CT-P70 and CT-P71, designed to target solid cancers. These therapeutics leverage the new payload 'PBX-7016,' which demonstrated low toxicity and high tumor growth inhibition (TGI) effects during development. The company also plans to develop dual-payload ADCs that incorporate two distinct payloads with complementary mechanisms of action, aiming to deliver a more potent cytotoxic response to cancer cells.

In addition, Celltrion is focusing on developing multispecific antibodies that selectively target cancer cells or are activated only under specific conditions. CT-P72, a tumor-selective multispecific antibody, has demonstrated improved on-target off-tumor toxicity through cytotoxic research results showing clear differences between normal tissue cells and cancer cells. The next-generation multispecific antibody therapeutics in development will focus on enhancing safety by conditional activation with 'conditionally-active multispecific antibodies (MsAb)' and maximizing therapeutic potential of tumor killing immune cells with 'immuno-oncology multispecific antibodies (MsAb).'



Celltrion's commitment to innovative drug development is evident in its goal to generate 40% of its revenue from innovative drugs by 2030. This aligns with the company's growth strategy, focusing on both biosimilars and innovative drug development to ensure sustainable growth. By expanding its portfolio to include advanced modalities such as ADCs and multi-specific antibodies, Celltrion aims to drive future growth and establish itself as a global player in novel drug development.

In conclusion, Celltrion's strategic vision for advancing its innovative drug pipeline, as outlined at the J.P. Morgan Healthcare Conference, demonstrates the company's commitment to driving future growth through a dual-track approach. With specific timelines and milestones for its 13 innovative drugs through 2028, Celltrion is poised to make significant strides in the development of next-generation ADCs and multispecific antibodies, ultimately enhancing the potential for successful cancer treatment.